Biotech Values

[iwfal]

Thanks. I too think softer sell is better, but for more than just ‘patient disappointment’ reasons. Eg FDA may force a change, which will be unpleasant especially if very public. And they have an important sBLA in review by the FDA, so pissing them off seems unwise.

RVNC can certainly promote Daxxify using published data from clinical trials.

This is not clear to me. Historically this was questionable, but perhaps the Amarin case changed that? Not something I’ve tracked in detail since the Amarin case, so …?